Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 41 Enz. Inhib. hit(s) with all data for entry = 50012514
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119815(3-chloro-4-[16-methyl-(12S)-2,10-diazatetracyclo[1...)
Affinity DataKi:  9nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119813(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  9nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119807(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  13nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119807(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  23nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119816(3-chloro-4-[16-methyl-(12R)-2,10-diazatetracyclo[1...)
Affinity DataKi:  30nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119812(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  32nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119813(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  40nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50065115(3-chloro-4-(10,11-dihydro-5H-benzo[e]pyrrolo[1,2-a...)
Affinity DataKi:  90nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119812(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  130nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119815(3-chloro-4-[16-methyl-(12S)-2,10-diazatetracyclo[1...)
Affinity DataKi:  130nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119817(2-Methyl-N-[4-(2,3,4,5-tetrahydro-benzo[b][1,4]dia...)
Affinity DataKi:  160nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119810(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  180nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119811(1N-{4-[6-chloro-16-ethyl-(12S)-2,10-diazatetracycl...)
Affinity DataKi:  520nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119811(1N-{4-[6-chloro-16-ethyl-(12S)-2,10-diazatetracycl...)
Affinity DataKi:  620nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119817(2-Methyl-N-[4-(2,3,4,5-tetrahydro-benzo[b][1,4]dia...)
Affinity DataKi:  890nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119810(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataKi:  2.60E+3nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119813(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  4nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119815(3-chloro-4-[16-methyl-(12S)-2,10-diazatetracyclo[1...)
Affinity DataIC50:  4nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119818(3-chloro-4-[16-ethyl-2,10-diazatetracyclo[11.2.1.0...)
Affinity DataIC50:  4nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119812(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  5nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50065115(3-chloro-4-(10,11-dihydro-5H-benzo[e]pyrrolo[1,2-a...)
Affinity DataIC50:  5nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119807(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  5nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119814(1N-{4-[16-ethyl-2,10-diazatetracyclo[11.2.1.02,12....)
Affinity DataIC50:  6nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119813(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  7nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119812(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  10nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119811(1N-{4-[6-chloro-16-ethyl-(12S)-2,10-diazatetracycl...)
Affinity DataIC50:  13nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119816(3-chloro-4-[16-methyl-(12R)-2,10-diazatetracyclo[1...)
Affinity DataIC50:  15nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119819(3-chloro-4-[16-ethyl-(12S)-2,10-diazatetracyclo[11...)
Affinity DataIC50:  19nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119815(3-chloro-4-[16-methyl-(12S)-2,10-diazatetracyclo[1...)
Affinity DataIC50:  24nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119807(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  24nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119810(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  26nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119817(2-Methyl-N-[4-(2,3,4,5-tetrahydro-benzo[b][1,4]dia...)
Affinity DataIC50:  28nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119809(3-chloro-4-[6-chloro-16-methyl-(12S)-2,10-diazatet...)
Affinity DataIC50:  30nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119809(3-chloro-4-[6-chloro-16-methyl-(12S)-2,10-diazatet...)
Affinity DataIC50:  35nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119811(1N-{4-[6-chloro-16-ethyl-(12S)-2,10-diazatetracycl...)
Affinity DataIC50:  35nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119808(1N-{4-[6-chloro-16-ethyl-(12S)-2,10-diazatetracycl...)
Affinity DataIC50:  59nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119810(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  68nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119808(1N-{4-[6-chloro-16-ethyl-(12S)-2,10-diazatetracycl...)
Affinity DataIC50:  72nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50065115(3-chloro-4-(10,11-dihydro-5H-benzo[e]pyrrolo[1,2-a...)
Affinity DataIC50:  150nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119817(2-Methyl-N-[4-(2,3,4,5-tetrahydro-benzo[b][1,4]dia...)
Affinity DataIC50:  250nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK-293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50119807(1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyc...)
Affinity DataIC50:  7.40E+3nMAssay Description:Inhibition of cytochrome P450 2C9More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed